Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Romero sues supplement firms

This article was originally published in The Tan Sheet

Executive Summary

Phillies reliever J.C. Romero sues supplement makers Ergopharm and Proviant Technologies, allegedly the firms failed to list all ingredients on the label of 6-OXO Extreme, a testosterone boosting supplement. In the suit filed April 27 in the Superior Court in Camden, N.J., Romero alleges the supplement caused him to test positive for substances banned by Major League Baseball, resulting in his suspension during the 2008 World Series and for the first 50 games of this season. He seeks compensatory and punitive damages. Proviant Technologies disputes the allegations and told media 6-OXO Extreme warns on the label that using the product may be banned by some sports leagues or government associations. Earlier this year, supplement maker AdvoCare accused a professional swimmer of defamation after she and her coach suggested to media that its products were tainted with a prohibitied performance-enhancing substance. The athlete has filed a liability and negligent claim against Carrollton, Texas.-based AdvoCare (1"The Tan Sheet" Feb. 23, 2009, p. 6)

You may also be interested in...

AdvoCare’s Suit Aims At Athletes Falsely Blaming Supplements For Failed Tests

A high-stakes legal battle about allegedly contaminated dietary supplements could make athletes who test positive for banned substances think twice before blaming dietary supplements

FDA To Ramp Up ASCA Pilot In 2021

A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts